Daclizumab definition

Daclizumab means any product that contains humanized anti-Tac (as defined under “Field”).
Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name “Daclizumab” by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.
Daclizumab means a [*] humanized murine monoclonal antibody prepared against the p55 component of IL-2R [*] and covered by claims under [*]

Examples of Daclizumab in a sentence

  • If a patient started an agent, stopped, and restarted with a break in between, enter as two separate agents reporting the start and end dates of both.⭘ Alemtuzumab (Campath)⭘ Basiliximab (Simulect)⭘ Bortezomib (Velcade)⭘ Daclizumab (Zenapax)⭘ OKT3⭘ Rituximab (Rituxan)⭘ Thymoglobulin (ATG)⭘ Unknown⭘ Other, specify Start Date (1993): Indicate the month, day, and year agent started.

  • Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

  • Charges for drugs like Basiliximab/ Daclizumab, HBIG, and peg interferon.

  • Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.

  • Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

  • Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.

  • Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS; Daclizumab Asthma Study Group.

  • Daclizumab, a monoclonal antibody, is in ongoing Phase III clinical trials for relapsing remitting MS.

  • Cer-tolizumab.- 15 Cetuximab.- 16 Daclizumab.- 17Denosumab.- 18 Eculizumab.- 19 Edrecolomab.- 20Efalizumab.- 21 Gemtuzumab.- 22 Golimumab.- 23Ibritumomab.- 24 Infliximab.- 25 Ipilimumab.- 26Muromonab.- 27 Natalizumab.- 28 Nimotuzumab.-29 Ofatumumab.- 30[...] Fields of interestBiomedicine (general); Medicine (general); Phar- macy Target groupsProfessional/practitioner Type of publicationMonographMore on www.springer.com/978-88-470-5312-0Hardcover2014.

  • ATGAM, Thymoglobulin, Basiliximab, Daclizumab) given soon after transplant (started within 3 days), not used to specifically treat a known or suspected rejection episode).


More Definitions of Daclizumab

Daclizumab as used in this Amended and Restated Agreement means any product that contains Daclizumab.

Related to Daclizumab

  • Licensed Compound means [***].

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • U.S. Territory means American Samoa, the Commonwealth of the Northern Mariana Islands, Guam, the Commonwealth of Puerto Rico, or the U.S. Virgin Islands.

  • Licensed Product means a product, method or service in the Licensed Field of Use, the making, having made, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent.

  • medicinal product means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Clinical means having a significant relationship, whether real or potential, direct or indirect, to the actual rendering or outcome of dental care, the practice of dentistry, or the quality of dental care being rendered to a patient;

  • Novartis shall have the meaning set forth in the Preamble.

  • orphan means a child who has no surviving parent caring for him or her;

  • Licensed Territory means worldwide.

  • MFDA means the Mutual Fund Dealers Association of Canada;

  • Manufacturing Technology means any and all patents, patent applications, Know-How, and all intellectual property rights associated therewith, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno- associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Active Pharmaceutical Ingredient or “API” means the active pharmaceutical substance of the Drug in bulk form prior to incorporation into the Product.

  • Licensed Products means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  • Merck has the meaning set forth in the preamble.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.